Asian Journal of Immunology

Immune Cell Counts, Systemic Immune Inflammation Index and Pan Inflammation Immune Value in Female Nigerian Breast Cancer Patients before Treatment

Mutiu Alani Jimoh

Department of Radiation Oncology, University of Ibadan and University College Hospital, Ibadan, Nigeria.

Fabian Victory Edem

Department of Immunology, University of Ibadan and University College Hospital, Ibadan, Nigeria.

Ganiyu Olatunbosun Arinola *

Department of Immunology, University of Ibadan and University College Hospital, Ibadan, Nigeria.

*Author to whom correspondence should be addressed.

---

Abstract

Introduction: Evidences suggest that breast cancer is associated with inflammation but blood based inflammation indices previously used to support this finding were calculated using only two blood cell parameters. The present study hypothesized that alterations of blood cell based inflammatory indices could differentiate breast cancer characteristics.

Objective: Considering the importance of immune cells in tumourigenesis, the present study investigated new inflammation index (pan inflammation immune value, PIIV), systemic immune inflammation index (SII), selected immune cell counts (neutrophils, lymphocytes, basophils and eosinophils) and platelets in breast cancer patients with different clinico-pathological characteristics.

Methods: A cross-sectional case-control study conducted on breast cancer patients from Radiation Oncology Department, University College Hospital, Ibadan, Nigeria. Blood cells were counted using automation while PIIV and SII were calculated in relation with breast clinico-pathological characteristics or patient’s attributes.

Results: Most of the patients (67.4%) had monocyte counts below normal reference range. Mean total white blood cell (WBC), lymphocyte and SII were significantly increased in breast cancer patients compared with control. Mean total WBC and lymphocyte counts were significantly raised in early stage-, well-differentiated- and non-metastatic- breast cancer patients. Mean monocyte count was raised in invasive lobular-, well differentiated-, non-metastatic- and single positive- breast cancer patients. PIIV were raised in early stage-, poorly differentiated- and triple positive breast cancer patients. Mean WBC count and SII were significantly higher in obese breast cancer patients while PIIV was significantly increased in normotensive patients that were less than 40yrs old at diagnosis.

Conclusion: The study concluded that monocytes and lymphocytes are important immune cells at the early stage of breast cancer and that immune cell, SII or PIIV has differentiating potential for breast cancer characteristics.

Keywords: Breast cancer, pan-immune-inflammation value, prognosis

---

---

---

References

Lin F, Zhang LP, Xie SY, Huang HY, Chen XY, Jiang TC, Guo L, Lin HX. Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer. Front Oncol. 2022;12:830138. DOI: 10.3389/fonc.2022.830138. PMID: 35494034; PMCID: PMC9043599

Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135–4148. DOI: 10.1002/cam4.2281

Mantas D, Kostakis ID, Machairas N, Markopoulos C. White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma. Oncology Letters. 2016;12: 1610-1614.

Available:https://doi.org/10.3892/ol.2016.4760

Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, Du C, Wang S, Wei B and Fu P: Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther. 2014;7:1743–1752. PubMed/NCBI

Available:https://www.ohsu.edu/lab-services/cbc-differential

Okoh VO, Felty Q, Parkash J, Poppiti R, Roy D. Reactive oxygen species via redox signaling to PI3K/AKT pathway contribute to the malignant growth of 4-hydroxy estradiol-transformed mammary epithelial cells. Plos One. 2013;8:e54206, Available:https://doi.org/10.1371/journal.pone.0054206.

Allin KH, Bojesen SE, Nordestgaard BG. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population. Int J Cancer. 2016; 139:1493–1500. Available:https://doi.org/10.1002/ijc.30194

Akinbami, A. et al. Full blood count pattern of pre-chemotherapy breast cancer patients in Lagos, Nigeria. Caspian J Intern Med. 2013;4:574–579.

Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, et al. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Gastroenterology. 2016;150(7):1646–1658. DOI: 10.1053/j.gastro.2016.02.040

Gu M, Zhai Z, Huang L, Zheng W, Zhou Y, Zhu R, Shen F and Yuan C: Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2015; (Epub ahead of print). View Article : Google Scholar : PubMed/NCBI

Şahin AB, Cubukcu E, Ocak B, Deligonul A, Oyucu Orhan S, Tolunay S, Gokgoz MS, Cetintas S, Yarbas G, Senol K, Goktug MR, Yanasma ZB, Hasanzade U, Evrensel T. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep. 2021;11(1):14662. DOI: 10.1038/s41598-021-94184-7.

PMID: 34282214; PMCID: PMC8289916.

Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20:224. DOI: 10.1186/s12935-020-01308-6 PMID: 32528232; PMCID: PMC7282128